World No. 1 tennis player Jannik Sinner tested positive twice for the anabolic steroid clostebol metabolite during the Indian Wells tournament and in an out-of-competition sample.
Despite the positive tests, an independent tribunal cleared Sinner to continue participating after he successfully appealed the provisional suspension, attributing the contamination to an over-the-counter spray used by his team member.
Sinner did lose ranking points and prize money from the Indian Wells tournament due to the failed tests.
The ITIA kept Sinner's case confidential for five months after the doping incidents, raising controversy for the delayed revelation involving the top-ranked player.
Fellow players criticized the inconsistencies in handling the case and questioned the fairness of anti-doping regulations and penalties in professional tennis.
The ruling on Sinner's case may face appeals from anti-doping agencies.
WADA and the Italian Anti-Doping Agency have the option to appeal the decision.
Despite the controversy, Sinner remains the top seed at the upcoming U.S. Open after winning the Cincinnati Open and is among the favorites to win the tournament, along with Djokovic and Alcaraz.
Sources: Reuters, New York Times, Independent, Newsweek, NBC News, Forbes, BBC, New York Post, Fox News, Spiegel, South China Morning Post, Al Jazeera, The Hindu, Zocalo, Times of India, fmImpacto, Asharq Al-Awsat, Republic World
This article was written in collaboration with Generative AI news company Alchemiq.
